Drug Management of Rheumatoid Arthritis in Covid-19 Context : Impact on Therapeutic De-escalation

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04393233

Acronym

RHUMACOVID

Enrollment

300

Registered

2020-05-19

Start date

2020-04-23

Completion date

2020-08-23

Last updated

2024-08-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID, Rheumatoid Arthritis

Brief summary

The current situation of Sars-Cov-2 pandemic generates fears in the general population. Among patients receiving long-term immunomodulatory drugs, especially in the context of auto-immune diseases, there may be legitimates interrogations about the appropriateness of continuing treatment, without modification, in the current context. Most patients with Juvenile Rheumatoid Arthritis benefit from long-term immunmodulatory therapy (DMARD - disease modifying anti-rheumatic drug), more or less combined with regular use of non-steroidal anti-inflammatory drugs (NSAIDs) or corticosteroids.The present study will characterize this issue by defining the proportion of patients whose usual treatment of Rheumatoid Arthritis has been modified in relation to the actual sanitary crisis.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Rheumatoid arthritis satisfying ACR/EULAR criteria * Ongoing DMARD therapy

Exclusion criteria

* Inhability to consent

Design outcomes

Primary

Measure	Time frame	Description
Reduction or discontinuation of the DMARD therapy in relation to the Covid-19 sanitary crisis	1 Day	Reduction or discontinuation of treatment with sDMARD, bDMARD or tsDMARD

Countries

France

Outcome results